Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Jiangxi Rimag Group Co., Ltd. Class H ( (HK:2522) ).
Jiangxi Rimag Group Co., Ltd. has entered into a strategic cooperation agreement with the Qingyang Government and Medical Image Insights to establish shared medical imaging centers and digital platforms. This collaboration aims to improve regional medical resource integration, expand market presence in Northwest China, and enhance the efficiency of medical data utilization, benefiting the company’s operations and stakeholders.
The most recent analyst rating on (HK:2522) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on Jiangxi Rimag Group Co., Ltd. Class H stock, see the HK:2522 Stock Forecast page.
More about Jiangxi Rimag Group Co., Ltd. Class H
Jiangxi Rimag Group Co., Ltd. operates in the medical imaging industry, focusing on integrating medical resources and providing standardized imaging services. The company is involved in developing digital platforms and shared imaging centers to enhance healthcare services.
Average Trading Volume: 11,679,884
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.1B
See more insights into 2522 stock on TipRanks’ Stock Analysis page.